STOCK TITAN

Pasithea Therapeutics Corp - ktta STOCK NEWS

Welcome to our dedicated news page for Pasithea Therapeutics (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pasithea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pasithea Therapeutics's position in the market.

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the activation of four U.S. clinical trial sites for Phase 1 trial of PAS-004, a next-generation MEK inhibitor for treating NF1 and other cancer indications. The company plans to open three more sites in Eastern Europe. Preliminary interim data is expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
clinical trial
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announces the invention of a crystalline form of PAS-004, extending patent protection to at least 2045. The company is focused on developing innovative treatments for CNS disorders, with a strong emphasis on expanding its patent portfolio and increasing the value of PAS-004 through additional CMC development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the FDA clearance to evaluate PAS-004, a macrocyclic MEK inhibitor, in patients with MAPK pathway driven advanced solid tumors. The phase 1 dose escalation study is expected to begin in Q1 2024, with an initial readout anticipated as early as Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
clinical trial
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns stockholder meeting to provide additional time for voting on charter amendment proposals. The reconvened meeting will take place on December 29, 2023, with the original record date remaining the same. Stockholders are encouraged to vote promptly, and proxies previously submitted will be voted at the adjourned meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1797.44%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) Holds Annual Meeting and Receives Overwhelming Support for Approved Proposals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (KTTA) announced positive preclinical results for PAS-004, a potential treatment for Central Nervous System disorders. PAS-004 demonstrated superior anti-tumor efficacy in lung and liver cancer models compared to FDA-approved MEK inhibitors. The company plans to start a Phase 1 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.33%
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns its annual meeting of stockholders to December 19, 2023, to allow additional time for stockholders to vote on proposals outlined in the Proxy Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) plans to submit PAS-004 IND application in the current quarter and begin a Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF, and NF1 mutations. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. Dr. Tiago Reis Marques, CEO of Pasithea, expressed excitement to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in early 2024 following acceptance of the IND by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
clinical trial
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the selection of a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody targeting α5β1 integrin, showing promise for the treatment of ALS. The antibody has been optimized for high affinity and specificity, ready for manufacturing and IND-enabling studies. Extensive preclinical studies have validated the candidate's efficacy in both sporadic and familial ALS mouse models, with potential implications for human patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. completes tender offer, purchasing all 5,323,451 shares at $0.70 per share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Pasithea Therapeutics Corp

Nasdaq:KTTA

KTTA Rankings

KTTA Stock Data

7.55M
754.00k
570.21%
23.88%
0.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miami Beach